Univariate analysis for OS and EFS
| . | 3-y OS (95% CI) . | P . | 3-y EFS (95% CI) . | P . |
|---|---|---|---|---|
| Age | ||||
| <10 | 87 (80-94) | .016 | 74 (65-83) | .221 |
| ≥10 | 68 (53-84) | 63 (48-79) | ||
| Calendar period | ||||
| 1990-2000 | 66 (46-87) | 53 (31-74) | ||
| 2001-2007 | 79 (68-90) | .028 | 70 (57-82) | .060 |
| 2008-2012 | 91 (84-94) | 79 (68-89) | ||
| Donor type | ||||
| HLA-matched related | 85 (75-95) | .005* | 77 (66-88) | .02† |
| HLA-matched unrelated | 85 (76-94) | 71 (60-83) | ||
| HLA mismatched | 55 (28-82) | 40 (13-67) | ||
| Source of cells | ||||
| BM | 82 (73-91) | 76 (66-86) | ||
| CB | 92 (81-100) | .128 | 70 (52-89) | .130 |
| PB | 75 (59-90) | 59 (42-76) | ||
| Conditioning regimen | ||||
| RIC | 76 (55-97) | .304 | 64 (41-87) | .373 |
| Myeloablative | 82 (75-90) | 71 (63-80) | ||
| GVHD prophylaxis | ||||
| CSA + MTX | 91 (82-99) | .038 | 81 (70-92) | .075 |
| No/only CSA | 79 (68-89) | 66 (54-78) | ||
| In vivo T-cell depletion (ATG) | ||||
| No | 82 (71-93) | .956 | 73 (61-85) | .714 |
| Yes | 82 (73-90) | 69 (59-79) | ||
| MDS/AL | ||||
| No MDS/leukemia | 87 (79-95) | .728 | 77 (67-87) | .405 |
| MDS/leukemia | 79 (57-100) | 64 (39-89) |
| . | 3-y OS (95% CI) . | P . | 3-y EFS (95% CI) . | P . |
|---|---|---|---|---|
| Age | ||||
| <10 | 87 (80-94) | .016 | 74 (65-83) | .221 |
| ≥10 | 68 (53-84) | 63 (48-79) | ||
| Calendar period | ||||
| 1990-2000 | 66 (46-87) | 53 (31-74) | ||
| 2001-2007 | 79 (68-90) | .028 | 70 (57-82) | .060 |
| 2008-2012 | 91 (84-94) | 79 (68-89) | ||
| Donor type | ||||
| HLA-matched related | 85 (75-95) | .005* | 77 (66-88) | .02† |
| HLA-matched unrelated | 85 (76-94) | 71 (60-83) | ||
| HLA mismatched | 55 (28-82) | 40 (13-67) | ||
| Source of cells | ||||
| BM | 82 (73-91) | 76 (66-86) | ||
| CB | 92 (81-100) | .128 | 70 (52-89) | .130 |
| PB | 75 (59-90) | 59 (42-76) | ||
| Conditioning regimen | ||||
| RIC | 76 (55-97) | .304 | 64 (41-87) | .373 |
| Myeloablative | 82 (75-90) | 71 (63-80) | ||
| GVHD prophylaxis | ||||
| CSA + MTX | 91 (82-99) | .038 | 81 (70-92) | .075 |
| No/only CSA | 79 (68-89) | 66 (54-78) | ||
| In vivo T-cell depletion (ATG) | ||||
| No | 82 (71-93) | .956 | 73 (61-85) | .714 |
| Yes | 82 (73-90) | 69 (59-79) | ||
| MDS/AL | ||||
| No MDS/leukemia | 87 (79-95) | .728 | 77 (67-87) | .405 |
| MDS/leukemia | 79 (57-100) | 64 (39-89) |